Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug-Sep;41(8-9):693-700.
doi: 10.1051/medsci/2025109. Epub 2025 Sep 8.

[New therapeutic approaches for the treatment of primary biliary cholangitis]

[Article in French]
Corentin Brice  1 , Alexandre Louvet  1
Affiliations
Review

[New therapeutic approaches for the treatment of primary biliary cholangitis]

[Article in French]
Corentin Brice et al. Med Sci (Paris). 2025 Aug-Sep.

Abstract
in English, French

Primary biliary cholangitis (PBC) is a rare disease for which management long consisted of a single treatment: ursodeoxycholic acid. In 2015-2016, this disease regained interest with the first studies on obeticholic acid (FXR agonist) and then on bezafibrate (PPAR agonist). Subsequently, over the past five years, significant progress has been made in the management of PBC. Major studies have helped better predict disease progression and its response to treatment through the development of prognostic tools. Additionally, the therapeutic arsenal has expanded with the arrival of selective PPAR agonists.

Title: Nouvelles pistes thérapeutiques pour le traitement de la cholangite biliaire primitive.

Abstract: La cholangite biliaire primitive est une maladie rare auto-immune qui cause une réduction ou un arrêt du flux biliaire pour laquelle la prise en charge a longtemps consisté en un traitement unique : l’acide ursodésoxycholique. Dans les années 2015-2016, cette maladie a connu un regain d’intérêt lors des premières études cliniques réalisées sur l’acide obéticholique (un agoniste du récepteur FXR) puis sur le bézafibrate (un agoniste du récepteur PPAR). Par la suite, de nombreux progrès ont été réalisés dans la prise en charge de la cholangite biliaire primitive. D’importantes études ont permis de mieux prédire le pronostic évolutif de la maladie, sa réponse au traitement par le développement d’outils pronostiques, et l’arsenal thérapeutique s’est étoffé avec l’arrivée de nouveaux agonistes PPAR sélectifs.

PubMed Disclaimer

References

    1. Hirschfield GM, Beuers U, Corpechot C, et al. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017 ; 67 : 145–72.
    1. Corpechot C, Gaouar F, Chrétien Y, et al. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol 2012 ; 56 : 218–24.
    1. Boonstra K, Kunst AE, Stadhouders PH, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int Off J Int Assoc Study Liver 2014 ; 34 : e31–8.
    1. Lleo A, Jepsen P, Morenghi E, et al. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep 2016 ; 6 : 25906.
    1. Dahlan Y, Smith L, Simmonds D, et al. Pediatric-onset primary biliary cirrhosis. Gastroenterology 2003 ; 125 : 1476–9.

MeSH terms

LinkOut - more resources